Weight loss drugs, such as those containing GLP-1 agonists like Wegovy and Mounjaro, have emerged as effective tools for ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

And although shares fell 35% from peak-to-trough, it became apparent that those who seek these weight-loss drugs also tend to ...

(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...

Ozempic and Wegovy are increasingly available in Australia and worldwide to treat type 2 diabetes and obesity. The dramatic ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

Weight loss drugs, such as those containing GLP-1 agonists like Wegovy and Mounjaro, have emerged as effective tools for people struggling to lose ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

The Medicines and Healthcare Products Regulatory Agency (MHRA) has ruled that warnings about the risk should now be added to drugs like Ozempic, Wegovy and Mounjaro.